Epitalon (Epithalon): What the Evidence Actually Shows

Grade CPending FDA rulemaking

Status first

Epitalon is not currently legal to compound. It passed the FDA advisory committee 7 to 5 in July 2026 and awaits formal rulemaking.

The short version

A four amino acid peptide developed in Russia, derived from pineal gland extract work.
Marketed almost entirely on telomerase and lifespan claims.
Those claims rest on a small body of Russian work that has not been replicated in the West.
This is the compound where the gap between marketing and evidence is widest.
Pending rulemaking. Not available.

What it is

Epitalon is a synthetic version of a peptide isolated from pineal extract, part of the Khavinson bioregulator line of research. It is claimed to activate telomerase and, by extension, to slow cellular aging.

Being straight about the evidence

The telomerase claim traces to a limited set of studies, largely from a single research group, published in venues that have not been widely replicated. There are reports of increased lifespan in rodents and small human cohorts followed over long periods.

None of that meets the standard you would want before injecting something to influence cellular aging. Telomerase activation is also not an unambiguously good thing: it is a mechanism cancer cells exploit, which is a serious question this compound's marketing does not address.

The concern nobody selling this mentions

Telomerase upregulation is a recognised feature of many cancers. A compound proposed to activate telomerase in healthy tissue raises an obvious question about tissue that is not healthy. There is no human safety data addressing it. Anyone with a cancer history should treat this as contraindicated and talk to an oncologist.

What this will not do

It will not extend your lifespan. No peptide has been shown to do that in humans.
It will not come with replicated Western evidence.

Full library · Safety and sourcing · Reconstitution calculator · Compound index

Regulatory status current as of the page date. This area is changing quickly and this page is reviewed monthly. [set review reminder]